SUSAN ESSING-SPILLER: Open Payments
NPI 1548612344 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,474 in 121 payments from 43 companies in 2025. Trend: 2023 $0 · 2024 $22 · 2025 $2,474
Food & beverage: $2,374Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $254 |
| Incyte Corporation | 6 | $214 |
| ABBVIE INC. | 11 | $209 |
| AstraZeneca Pharmaceuticals LP | 6 | $139 |
| PharmaEssentia USA Corporation | 5 | $101 |
| TerSera Therapeutics LLC | 4 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $97 |
| Janssen Biotech, Inc. | 5 | $94 |
| E.R. Squibb & Sons, L.L.C. | 5 | $92 |
| Merck Sharp & Dohme LLC | 5 | $88 |
Products named: VENCLEXTA, Fabhalta, KISQALI, BESREMI, OPDIVO, KEYTRUDA, XTANDI, RYTELO.
Industry payments across IN — which companies pay providers there.
